Comirnaty and Pfizer-BioNTech COVID-19 Vaccine

On August 23, 2021, the FDA approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

Source:

https://www.fda.gov/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine

Following the FDAs move to approve the Pfizer-BioNTech COVID-19 Vaccine, provided herein is information concerning COMIRNATY which can be found on the WHO VigiAccess database.

VigiAccess was launched by the World Health Organization (WHO) in 2015 to provide public access to information in VigiBase, the WHO global database of reported potential side effects of medicinal products.

Comirnaty contains the active ingredient(s): Covid-19 vaccine. Result is presented for the active ingredient(s). Total number of records retrieved: 1778489.

http://www.vigiaccess.org/